Con esta herramienta te facilitamos un acceso a todas las ofertas y demandas de tecnología europeas y a búsquedas de socios para participar en propuestas europeas de I+D publicadas en la red Enterprise Europe Network, pudiendo filtrar los resultados para facilitar las búsquedas más acordes con tus necesidades.

¿Quieres recibir estos listados de oportunidades de colaboración en tu correo de forma periódica y personalizada? Date de alta en nuestro Boletín

Para optimizar los resultados de la búsqueda, se recomienda utilizar términos en inglés.

Kit para predecir la respuesta al tratamiento con fármacos antipsicóticos

Resumen

Tipo:
Oferta Tecnológica
Referencia:
TOES20170529001
Publicado:
26/06/2017
Caducidad:
26/06/2018
Resumen:
Un instituto español de investigación médica ha desarrollado un método para predecir, antes del tratamiento, la respuesta clínica individual a medicación antipsicótica en individuos que padecen trastornos psicóticos. El método se basa en un perfil de expresión génica y permite seleccionar pacientes para continuar con el tratamiento o aplicar tratamientos antipsicóticos alternativos. El instituto busca empresas interesadas en comercializar el kit bajo acuerdos de licencia o en probar los fármacos mediante acuerdos de servicio. Asimismo busca acuerdos de investigación para desarrollar el kit.

Details

Tittle:
A kit for predicting the therapeutic response to antipsychotic drugs
Summary:
A Spanish healthcare research institute has developed a method for predicting, before treatment, the individual clinical response to antipsychotic medication in subjects suffering from psychosis disorders.
The institute would like to get in contact with companies interested in commercializing this kit under a license agreement or a services agreement to test the drugs. Also a research cooperation agreement to develop the kit will be considered.
Description:
A Spanish healthcare research institute in collaboration with other scientific agents has developed a method for predicting, before treatment, the individual clinical response to antipsychotic medication in subjects suffering from psychosis disorders. This method is based on a gene expression profile and allows the selection of patients for further or alternative antipsychotic therapies.
Antipsychotic drugs, also termed as tranquilizers or neuroleptics, are the cornerstone to treat psychotic disorders such as schizophrenia. They are also majorly used to treat several other psychotic disorders including bipolar disorder, delirium, dementia and psychotic depression and they can be also used to treat severe depression, personality disorders, autism and anxiety. Therefore, antipsychotic medications are among the most common and costly prescribed drugs with significant increases in overall prescription in recent years.
An adequate treatment at initial stages of the psychotic disorder is crucial to improve the prognosis of this clinical condition.
Despite being one of the largest types of prescribed drugs and having large inter-individual differences in efficacy, no methodology to predict the treatment response in patients with psychotic disorders is currently available. There are no molecular tests available that allow predicting the clinical response to antipsychotic treatments.
Here the research institute presents a method for predicting, before treatment, the individual clinical response to antipsychotic medication in subjects suffering from psychosis disorders. This method is based on a gene expression profile and allows the selection of patients for further or alternative antipsychotic therapies.
Particularly, the inventors have identified six-genes whose expression profile, preferably measured in blood samples collected from the patient, provides useful information to predict the clinical response to antipsychotics in psychotic patients.

The institute would like to talk to companies interested in commercializing this kit under a license agreement or a services agreement to test the drugs. The company will also consider a research cooperation agreement to develop the kit.
Advantages and Innovations:
No methodology to predict the treatment response in patients with psychotic disorders is currently available.
The main competitive advantages of the predictor kit are:
- It is useful to predict the therapeutic response to antipsychotics in drug - naïve patients.
- It allows the selection of patients for further or alternative antipsychotic therapies.
- It is useful for the identification, in early stages before the treatment, of those patients that will or will not respond to the antipsychotic drugs, which allow designing specific individual therapeutic strategies for each patient.
Stage of Development:
Under development/lab tested
IPs:
Patent(s) applied for but not yet granted
CommeR Statunts Regarding IPR Status:
A Spanish patent application covering this product was filed on 29th march, 2017

Partner sought

Type and Role of Partner Sought:
Pharmaceutical companies involved in antipsychotic drugs that may be interested in:
- License agreement: to commercialise a kit to predict response to antipsychotic drugs.
- Service agreement: pharmaceutical companies interested in contracting the research institute services to test the drugs with its genetic profile.
- Research agreement: to develop the kit to predict response to antipsychotic drugs.

Client

Type and Size of Client:
R&D Institution
Already Engaged in Trans-National Cooperation:
Si
Languages Spoken:
English
French
Spanish

Keywords

Technology Keywords:
06001005 Diagnósticos, diagnosis
06001012 Investigaciones médicas
03004007 Pharmaceutics
06001015 Productos farmacéuticos / medicamentos
06002003 Tecnología de enzimas